Significant Blood Pressure Reduction at 24 Months After Renal Denervation System Treatment
Published date : 20 March 2013
Article date : 20 March 2013
A press release from Medtronic has announced 24 month data from Symplicity HTN-2 - the first randomised clinical trial investigating renal denervation. The data show patients initially randomised to treatment with the Symplicity renal denervation system sustained a significant drop in blood pressure. Additionally, 26 subjects in the control group who crossed-over and received renal denervation following assessment of the six-month primary endpoint had an average blood pressure reduction at 24 months.
According to the manufacturer, the 24 month average blood pressure reductions demonstrate preservation of the blood pressure reduction for both groups reported previously at 6, 12, and 18-month follow-up.
There were no device-related serious adverse events, no late vascular complications and no significant decline in kidney function compared to pre-procedure values reported out to 24 months post-procedure. The Symplicity renal denervation system is only available for investigational use in the United States and Japan.
At 24 months, pulse pressure improved significantly for patients in this analysis following treatment with the Symplicity system -18.5 mm Hg from baseline for the initial treatment group; and -22.5 mm Hg from baseline for the crossover group.
Source: Medtronic Press Office, 10 March 2013.
